Cunlong Zhang, Chunyan Tan, Huaiwei Ding, Tian Xin and Yuyang Jiang Pages 2921 - 2935 ( 15 )
Angiogenesis and vasculogenesis, regulated by VEGF/VEGFR signaling pathways, play key roles in tumor growth and metastasis. Selective inhibition of VEGFR kinase has been explored as a highly successful clinical strategy in cancer treatment. A number of VEGFR inhibitors have been approved in clinical use and many more are in various stages of drug development. This paper reviews selective small-molecule VEGFR inhibitors in clinical uses and in clinical trials, with particular focus on in vitro, in vivo and clinical trial results of these inhibitors. The VEGF/VEGFR genes and signaling pathways involved in tumor angiogenesis, and the strategies for accessing and improving the therapeutic efficacy of VEGFR inhibitors are also discussed.
Selective, VEGFR inhibitor, anticancer, angiogenesis, vasculogenesis, tumor growth, metastasis, clinical trials, signaling pathways, growth factors
, Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, China.